Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bituminosulfonate→

Bituminosulfonate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
8029-68-3
Molecular formula
Not available
Molecular weight
Not available
Drug class
Ammonium bituminosulfonate (ichthammol)topical anti-inflammatory and antiseptic preparation
Mechanism of action
A complex mixture of sulfonated shale-oil derivatives with local anti-inflammatory, antiseptic and keratoplastic properties. The active constituents and precise mechanism are not fully defined.
Indications / reported uses
  • Topical symptomatic treatment of selected inflammatory skin conditions, boils and superficial skin irritation in countries where ichthammol products are authorised; formulation and concentration determine use

Sources: NLM MeSH — Ichthammol / ammonium bituminosulfonate · PubMed — Ichthammol topical dermatology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bituminosulfonate Environmental Risk Assessment (ERA) (the Bituminosulfonate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.